Page last updated: 2024-10-28

hydroxychloroquine and Hyperkalemia

hydroxychloroquine has been researched along with Hyperkalemia in 2 studies

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

Hyperkalemia: Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Gautret, P2
Honoré, S2
Lagier, JC2
Raoult, D2
Hoang, VT1

Other Studies

2 other studies available for hydroxychloroquine and Hyperkalemia

ArticleYear
Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.
    International journal of antimicrobial agents, 2021, Volume: 57, Issue:1

    Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVI

2021
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
    International journal of antimicrobial agents, 2021, Volume: 57, Issue:1

    Topics: Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Clinical Trials as Topic; COVI

2021